Update on propranolol for infantile hemangioma: Where are we now?

Amanda A. Cyrulnik; Sharon A. Glick

doi:10.1542/neo.16-1-e16

Update on propranolol for infantile hemangioma: Where are we now?

Amanda A. Cyrulnik, Sharon A. Glick

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

Original language	English (US)
Pages (from-to)	e16-e25
Journal	NeoReviews
Volume	16
Issue number	1
DOIs	https://doi.org/10.1542/neo.16-1-e16
State	Published - Jan 1 2015
Externally published	Yes

ASJC Scopus subject areas

General Medicine

Access to Document

10.1542/neo.16-1-e16

Cite this

@article{eaafa96898f54aa99aa138b2e76c8590,

title = "Update on propranolol for infantile hemangioma: Where are we now?",

abstract = "The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.",

author = "Cyrulnik, {Amanda A.} and Glick, {Sharon A.}",

year = "2015",

month = jan,

day = "1",

doi = "10.1542/neo.16-1-e16",

language = "English (US)",

volume = "16",

pages = "e16--e25",

journal = "NeoReviews",

issn = "0191-9601",

publisher = "American Academy of Pediatrics",

number = "1",

}

TY - JOUR

T1 - Update on propranolol for infantile hemangioma

T2 - Where are we now?

AU - Cyrulnik, Amanda A.

AU - Glick, Sharon A.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

AB - The discovery of propranolol for the treatment of infantile hemangioma in 2008 has revolutionized management of this condition. Hundreds of reports have corroborated the initial published findings that propranolol is a safe and efficacious therapeutic agent. Furthermore, it is well tolerated in infants and can markedly alter the natural history and potential disfigurement of these lesions. The goal of this review is to outline the salient features of infantile hemangioma and the optimal use of propranolol as a first-line treatment modality.

UR - http://www.scopus.com/inward/record.url?scp=84920413948&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84920413948&partnerID=8YFLogxK

U2 - 10.1542/neo.16-1-e16

DO - 10.1542/neo.16-1-e16

M3 - Article

AN - SCOPUS:84920413948

SN - 0191-9601

VL - 16

SP - e16-e25

JO - NeoReviews

JF - NeoReviews

IS - 1

ER -

Update on propranolol for infantile hemangioma: Where are we now?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this